Related Experiment Videos
MIF as a disease target: ISO-1 as a proof-of-concept therapeutic
Yousef Al-Abed1, Sonya VanPatten
1Department of Medicinal Chemistry, The Feinstein Institute for Medical Research, North Shore/LIJ Health System, Manhasset, NY 11030, USA. yalabed@nshs.edu
Abstract:
Macrophage migration inhibitory factor (MIF) is a pleiotropic proinflammatory cytokine that has been implicated as playing a causative role in many disease states, including sepsis, pneumonia, diabetes, rheumatoid arthritis, inflammatory bowel disease, psoriasis and cancer. To inhibit the enzymatic and biologic activities of MIF, we and others have developed small-molecule MIF inhibitors. Most MIF inhibitors bind within the hydrophobic pocket that contains highly conserved amino acids known to be essential for MIF's proinflammatory activity. The best characterized of these small-molecule MIF inhibitors, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) has been validated in scores of laboratories worldwide. Like neutralizing anti-MIF antibodies, ISO-1 significantly improves survival and reduces disease progression and/or severity in multiple murine models where MIF is implicated. This MIF inhibitor, its derivatives and other MIF-targeted compounds show great promise for future testing in disease states where increased MIF activity has been discovered.
Insights
Small-molecule inhibitors targeting macrophage migration inhibitory factor (MIF) show promise for treating inflammatory diseases. The compound ISO-1 effectively reduces disease severity and improves survival in preclinical models, highlighting its therapeutic potential.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine linked to various diseases.
- Inhibiting MIF's activity is a therapeutic strategy for inflammatory conditions.
- Small-molecule inhibitors target MIF's essential hydrophobic pocket.
Purpose of the Study:
- To evaluate the efficacy of small-molecule MIF inhibitors.
- To investigate the therapeutic potential of ISO-1 in disease models.
Main Methods:
- Development of small-molecule MIF inhibitors.
- Validation of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) in multiple laboratories.
- Testing ISO-1 in murine models of MIF-implicated diseases.
Main Results:
- ISO-1 significantly improves survival in disease models.
- ISO-1 reduces disease progression and severity.
- ISO-1's mechanism involves binding to MIF's hydrophobic pocket.
Conclusions:
- Small-molecule MIF inhibitors, particularly ISO-1, are effective in preclinical models.
- ISO-1 demonstrates therapeutic promise for diseases involving elevated MIF activity.
- Further investigation of MIF-targeted compounds is warranted for clinical application.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...